erbB-2 overexpression in human mammary epithelial cells confers growth factor independence

Endocrinology

Volumn 140, Issue 8, 1999, Pages 3615-3622

  Woods Ignatoski, Kathleen M ^a   LaPointe, Allison J ^a   Radany, Eric H ^a   Ethier, Stephen P ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INSULIN; PROTEIN P53;

ARTICLE; BREAST EPITHELIUM; CELL ACTIVATION; CELL GROWTH; CELL SUBPOPULATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0033304746     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.8.6939     Document Type: Article

References (55)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
3. Structure and expression of c-erbB-2 and EGF receptor genes inflammatory and non-inflammatory breast cancer: Prognostic significance
4. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
5. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases
6. c-erbB-2 Amplification in node-negative human breast cancer
7. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene
8. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
9. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer
10. Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma
11. HER-2/neu amplification predicts poor survival in node-positive breast cancer
12. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas
13. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation
14. Structural analysis of p185(c-neu) and epidermal growth factor receptor tyrosine kinases: Oligomerization of kinase domains
15. Identification of heregulin, a specific activator of p185erb2
16. Cell-type specific interaction of neu differentiation factor (NDF heregulin) with neu/ HER-2 suggests complex ligand receptor relationships
17. Heregulin induces tyrosine phosphorylation of HER4/P180(erbB4)
18. The erbB3 gene product is a receptor for heregulin
19. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
20. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling
21. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells
22. NDF/heregulin stimulates the phosphorylation of Her3/erbB3
23. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells
24. Heregulin-dependent regulation cf HER2/neu oncogenic signaling by heterodimerization with HER3
25. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
26. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
27. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
28. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
29. The influence of growth factors on the proliferative potential of normal and primary breast cancer-derived human breast epithelial cells
30. Phosphatidylinositol 3-kinase recruitment by p185(erbB-2) and erbB-3 is potently induced by neu differentiation factor/ heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification
31. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes erbB-3 signaling from that of other erbB EGFr family members
32. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
33. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites
34. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1 - Stimulation by insulin and inhibition by Wortmannin
35. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70S6 kinase, DNA synthesis, and glucose transporter translocation
36. The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors
37. Mechanism of activation of protein kinase B by insulin and IGF-1
38. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
39. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine phosphorylated erbB-2
40. Novel mechanisms of E2F induction by BK virus large T antigen: Requirement of both the pRb binding and J domains
41. Tumor progression in four mammary epithelial cell lines derived from the same patient
42. Importance of extended growth potential and growth factor independence on in vivo neoplastic potential of primary rat mammary carcinoma cells
43. Multiple growth factor independence in rat mammary carcinoma cells
44. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha
45. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines
46. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein
47. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
48. Potent activation of phosphatidylinositol 3'-kinase by simple phosphotyrosine peptides derived from insulin receptor substrate 1 containing two YMXM motifs for binding SH2 domains
49. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and raf-1/mitogen-activated protein kinase pathway activation
50. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis
51. Akt is a direct target of the phosphatidylinositol 3-kinase
52. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate
53. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
54. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
55. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt